Figure S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
- Amr El Zawily (14851115)
- Frederick S. Vizeacoumar (14851118)
- Renuka Dahiya (14851121)
- Sara L. Banerjee (14851124)
- Kalpana K. Bhanumathy (14851127)
- Hussain Elhasasna (14851130)
- Glinton Hanover (14851133)
- Jessica C. Sharpe (14851136)
- Malkon G. Sanchez (14851139)
- Paul Greidanus (14851142)
- R. Greg Stacey (14851145)
- Kyung-Mee Moon (14851148)
- Ilya Alexandrov (14851151)
- Juha P. Himanen (14851154)
- Dimitar B. Nikolov (14851157)
- Humphrey Fonge (14851160)
- Aaron P. White (14851163)
- Leonard J. Foster (8976302)
- Bingcheng Wang (14851166)
- Behzad M. Toosi (14851169)
- Nicolas Bisson (14851172)
- Tajib A. Mirzabekov (14851175)
- Franco J. Vizeacoumar (14851178)
- Andrew Freywald (14851181)
Publication date
July 2023
DOI Publisher
American Association for Cancer Research (AACR)Abstract
Fig. S4. A. Heatmap of the shRNA screen hits that are enriched in the top 15 GO processesgenerated using GSEA software. B. Gene Set Enrichment Analysis plots of the top 15 GOprocess for the shRNA screen data produced by GSEA software used to generate the heatmap inA.</p
Add to ORKG